By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
Medical Information, Documents, News - TheMediTary.Com Logo Medical Information, Documents, News - TheMediTary.Com Logo

TheMediTary.Com

Medical Information, Documents, News - TheMediTary.Com

  • Home
  • News
  • Drugs
  • Drugs A-Z
  • Medical Answers
  • About Us
  • Contact
Medical Information, Documents, News - TheMediTary.Com Logo Medical Information, Documents, News - TheMediTary.Com Logo
Search Drugs
  • Drugs
    • Latest Drugs
    • Drugs A-Z
    • Medical Answers
  • News
    • FDA Alerts
    • Medical News
    • Health
    • Consumer Updates
    • Children's Health
  • More TheMediTary.Com
    • About Us
    • Contact
Follow US
Home > Drugs > Antiviral combinations > Casirivimab and imdevimab
Antiviral combinations

Casirivimab and imdevimab

https://themeditary.com/drug/casirivimab-and-imdevimab-1187.html
Medically Reviewed by Oluni Odunlami, MD TheMediTary.Com | Reviewed: Jul 13, 2023  Additional Content by TheMediTary.Com

Generic name: casirivimab and imdevimab (regen-cov) [ kas-i-riv-i-mab-and-im-dev-i-mab ]

Drug class: Antiviral combinations

Dosage form: injectable solution (1332 mg/11.1 ml-1332 mg/11.1 ml; 1332 mg/11.1 ml-300 mg/2.5 ml; 300 mg/2.5 ml-1132 mg/11.1 ml; 300 mg/2.5 ml-300 mg/2.5 ml; 600 mg-600 mg/10 ml)

Availability: Prescription only

Pregnancy & Lactation: Risk data not available

Brand names: Regen-cov

Contents
Uses Warnings Before Taking Dosage Side effects Interactions

What is Casirivimab and imdevimab?

Due to the high frequency of the Omicron BA.2 sub-variant, this drug is not currently authorized in any US region; therefore, this drug may not be administered for treatment of COVID-19 under the EUA until further notice by the US FDA.

Casirivimab and imdevimab are experimental medicines being studied for use in treating conditions caused by coronavirus. It is not yet known if casirivimab or imdevimab are safe and effective.

Casirivimab and imdevimab are also for use in people who have been exposed to COVID-19 and:

  • are not fully vaccinated against COVID-19; or

  • are vaccinated but may not have built up enough immunity (because they have certain diseases or use certain medicines), and have been or may be exposed to people who are infected with COVID-19.

Casirivimab and imdevimab are for use in adults and children at least 12 years old who weigh at least 88 pounds (40 kilograms).

The risk of COVID-19 symptoms becoming severe may be higher in people who:

  • are overweight;

  • have chronic kidney disease;

  • have diabetes;

  • have a weak immune system (caused by disease or by using certain medicine);

  • have sickle cell disease;

  • have a heart problem or high blood pressure;

  • have a neurodevelopmental disorder such as cerebral palsy;

  • have asthma or other chronic breathing disorder; or

  • have a tracheostomy, gastrostomy, or positive pressure ventilation (not related to COVID-19).

There also may be a higher risk of severe COVID-19 symptoms in pregnant women and in adults who are 65 and older.

Casirivimab and imdevimab are mixed together into a single solution called Regen-Cov.

Casirivimab and imdevimab have not been approved to treat coronavirus or COVID-19. However, these medicines may help prevent the need for emergency medical care or admission to a hospital because of COVID-19. Regen-Cov is not authorized for use in people who are already in the hospital or receiving supplemental oxygen for COVID-19.

Casirivimab and imdevimab may also be used for purposes not listed in this medication guide.

Related/similar drugs

Paxlovid, molnupiravir, Actemra, remdesivir, Lagevrio, nirmatrelvir / ritonavir

Warnings

Due to the high frequency of the Omicron BA.2 sub-variant, this drug is not currently authorized in any US region; therefore, this drug may not be administered for treatment of COVID-19 under the EUA until further notice by the US FDA.

How should I use Casirivimab and imdevimab

Regen-Cov is injected under the skin or into a vein by a healthcare provider.

When injected into a vein, Regen-Cov is given slowly over 20 to 50 minutes or longer. When injected under the skin, Regen-Cov is given as 2 to 4 separate injections into different areas of your body.

You will be watched for a short time after injection, to make sure you do not have an allergic reaction.

Regen-Cov is usually given as only one dose as soon as possible after you are exposed to or test positive for COVID-19, or within 10 days after the start of symptoms. You may need additional monthly doses if you continue to be exposed to COVID-19.

Being treated with Regen-Cov will not make you less contagious to other people. Keep using infection control methods such as self-isolation, social distancing, hand-washing, using protective face covering, disinfecting surfaces you touch a lot, and not sharing personal items with others.

Regen-Cov also may not keep you from becoming infected with coronavirus again. Being treated with this drug combination could also affect your body's immune response to a coronavirus vaccine. Casirivimab and imdevimab are still being studied and all of their risks are not yet known.

Detailed REGEN-COV dosage information
Casirivimab and imdevimab Dosage information (more detail)

Before Taking

Tell your doctor if you have ever had:

  • a COVID-19 vaccine;

  • a severe allergic reaction to a COVID-19 vaccine;

  • any serious or chronic illness;

  • any allergies; or

  • if you are pregnant or breastfeeding.

COVID-19 is more likely to cause serious illness or death in a pregnant woman. Not all risks are known yet, but being treated with casirivimab and imdevimab is likely to be less harmful than being infected with COVID-19 during pregnancy.

What happens if I miss a dose?

Call your doctor for instructions if you are on a monthly dose schedule and you miss an appointment for your injection.

What happens if I overdose?

In a medical setting an overdose would be treated quickly.

What should I avoid while using Casirivimab and imdevimab?

Follow your doctor's instructions about any restrictions on food, beverages, or activity.

Casirivimab and imdevimab side effects

Get emergency medical help if you have signs of an allergic reaction: hives, itching; difficult breathing; swelling of your face, lips, tongue, or throat.

Some side effects may occur during the injection. Tell your caregiver right away if you have:

  • throat irritation, swelling in your face or throat;

  • dizziness, a light-headed feeling (like you might pass out);

  • chest pain, wheezing, shortness of breath;

  • fever, chills, sweating, nausea, flushing (sudden warmth, redness, or tingly feeling);

  • fast or slow heartbeats, headache, pounding in your neck or ears;

  • weakness, tiredness;

  • rash, itching; or

  • muscle pain.

Call your doctor if you have new or worsening symptoms after the infusion, such as fever, confusion, weakness, tiredness, trouble breathing, or fast or slow heartbeats.

Less serious side effects may also occur, or you may have none at all. Not all possible side effects are known.

This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

Warnings

Due to the high frequency of the Omicron BA.2 sub-variant, this drug is not currently authorized in any US region; therefore, this drug may not be administered for treatment of COVID-19 under the EUA until further notice by the US FDA.

Before taking this medicine

Tell your doctor if you have ever had:

  • a COVID-19 vaccine;

  • a severe allergic reaction to a COVID-19 vaccine;

  • any serious or chronic illness;

  • any allergies; or

  • if you are pregnant or breastfeeding.

COVID-19 is more likely to cause serious illness or death in a pregnant woman. Not all risks are known yet, but being treated with casirivimab and imdevimab is likely to be less harmful than being infected with COVID-19 during pregnancy.

How is casirivimab and imdevimab given?

Regen-Cov is injected under the skin or into a vein by a healthcare provider.

When injected into a vein, Regen-Cov is given slowly over 20 to 50 minutes or longer. When injected under the skin, Regen-Cov is given as 2 to 4 separate injections into different areas of your body.

You will be watched for a short time after injection, to make sure you do not have an allergic reaction.

Regen-Cov is usually given as only one dose as soon as possible after you are exposed to or test positive for COVID-19, or within 10 days after the start of symptoms. You may need additional monthly doses if you continue to be exposed to COVID-19.

Being treated with Regen-Cov will not make you less contagious to other people. Keep using infection control methods such as self-isolation, social distancing, hand-washing, using protective face covering, disinfecting surfaces you touch a lot, and not sharing personal items with others.

Regen-Cov also may not keep you from becoming infected with coronavirus again. Being treated with this drug combination could also affect your body's immune response to a coronavirus vaccine. Casirivimab and imdevimab are still being studied and all of their risks are not yet known.

What other drugs will affect Casirivimab and imdevimab?

Other drugs may affect casirivimab and imdevimab, including prescription and over-the-counter medicines, vitamins, and herbal products. Tell your doctor about all other medicines you use.

More about Casirivimab and imdevimab (Casirivimab and imdevimab (regen-cov) [ kas-i-riv-i-mab-and-im-dev-i-mab ])

Dosage information
Drug images
Side effects
Drug class: Antiviral combinations

Related treatment guides

COVID-19
Post-Exposure Prophylaxis of COVID-19
Share this Article
Contents
Uses Warnings Before Taking Dosage Side effects Interactions
Related Drugs
Fidanacogene Elaparvovec
Cerave Anti-Itch
Centrum Adult
Crovalimab
Cyltezo Prefilled Syringe
Zepbound Pen
Mylanta One
Uretron Ds
Medihoney Wound And Burn Dressing
Lidotrode

Other drugs

Name Drug Class Updated
Fidanacogene Elaparvovec Drugs 03-Oct-2024
Cerave Anti-Itch Drugs 02-Oct-2024
Centrum Adult Drugs 02-Oct-2024
Crovalimab Drugs 02-Oct-2024
Cyltezo Prefilled Syringe Drugs 01-Oct-2024
Zepbound Pen Drugs 30-Sep-2024
Mylanta One Drugs 27-Sep-2024
Uretron Ds Drugs 27-Sep-2024
Medihoney Wound And Burn Dressing Drugs 26-Sep-2024
Lidotrode Drugs 26-Sep-2024
Libervant Drugs 26-Sep-2024
Moderna Covid-19 Drugs 25-Sep-2024
Beqvez Drugs 24-Sep-2024
Beqvez Drugs 24-Sep-2024
Beqvez Drugs 24-Sep-2024

Categories

  • FDA Alerts
  • Medical News
  • Health
  • Consumer Updates
  • Children's Health

About US

Welcome to TheMediTary.Com

Our website provides reliable and up-to-date information on various medical topics. We empower individuals to take charge of their health by simplifying complex medical jargon and providing practical tips and advice. We prioritize the privacy and confidentiality of our users and welcome feedback to improve our services.

Website use data of FDA and other sources

DMCA.com Protection Status Truste Protection Status Trust Mark Protection Status
HONcode logo We comply with the HONcode standard for trustworthy health information.
Quick Link
  • About Us
  • Contact Us
  • Editorial Policy
  • Privacy Policy
  • Accessibility Policy
  • Terms & Conditions
  • Disclaimer
  • DMCA
  • Do Not Sell My Personal Information
  • Sitemap
  • Care Notes
  • Health Guide
  • Professional
Drugs
  • New Drugs
  • Medical Answers
  • Drugs A-Z
  • Drug Classes
  • Drug Dosage
  • Pill Identifier
  • Consumer Infor
  • Side Effects
  • Inactive Ingredients
  • Pregnancy Warnings
  • Patient Tips
  • Treatments
News
  • Latest News
  • FDA Alerts
  • Medical News
  • Health
  • Consumer Updates
  • Children's Health
Find US
  • Medium
  • Google Site
  • Blogspot
  • API
  • Reddit
  • Tumblr
  • Scoop.it
  • Substack
  • Wordpress
  • Wix
  • Behance

© 2025 TheMediTary.Com All rights reserved. Operated by